Skip to main content
SpringerLink
Log in

Serum folate and prostate-specific antigen in the United States

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

Increased evidence suggests that folate may play a significant role in cancer development. This study investigates the association between levels of serum folate and prostate-specific antigen (PSA), a biomarker for prostate cancer detection.

Methods

Using data from the 2007 to 2010 National Health and Nutrition Examination Survey, a total of 3,293 men aged 40 years and older with serum PSA and folate measures were studied. Total PSA level (tPSA) and percent free/total PSA ratio (%fPSA) were major outcomes. The alternative cutpoints were used to categorize these measures as higher risks of prostate cancer (tPSA: ≥10, ≥4, and ≥2.5 ng/ml; %fPSA: ≤15 and ≤5 %). Serum folate level was analyzed as continuous and as quintiles. Association between serum folate and PSA levels were evaluated by multivariate linear and logistic regressions.

Results

Higher serum folate levels were associated with decreased log10-transformed tPSA (β = −001, p = 0.061) and increased %fPSA (β = 0.064, p = 0.012). Adjusting for age, race/ethnicity, socioeconomic status, use of non-steroidal anti-inflammatory drugs, body mass index, and smoking status, higher serum folate (fifth quintile) was associated with lower odds of having higher tPSA (≥10 ng/ml) and lower %fPSA (≤25 %): (tPSA: odds ratio, OR associated with fifth to first quintile of folate level = 0.42; 95 % confidence interval, CI = 0.21, 0.83; p for trend = 0.022 and %fPSA: OR = 0.71; 95 % CI = 0.52, 0.95; p for trend = 0.044).

Conclusions

Results of this study suggest that higher folate status may be protective against elevated PSA levels among men without diagnosed prostate cancer. Additional epidemiologic studies are necessary to confirm our findings and to investigate potential mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stover PJ (2004) Physiology of folate and vitamin B12 in health and disease. Nutr Rev 62:S3–S12; discussion S3

    Article  PubMed  Google Scholar 

  2. Ulrich CM, Potter JD (2006) Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15:189–193

    Article  PubMed  Google Scholar 

  3. Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130:129–132

    PubMed  CAS  Google Scholar 

  4. Kim YI (2004) Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 80:1123–1128

    PubMed  CAS  Google Scholar 

  5. American Cancer Society (2013) Cancer Facts & Figures 2013

  6. Ho E, Beaver LM, Williams DE, Dashwood RH (2011) Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (Bethesda, Md.) 2: 497–510

    Google Scholar 

  7. Kim YI (2003) Role of folate in colon cancer development and progression. J Nutr 133:3731S–3739S

    PubMed  CAS  Google Scholar 

  8. Kennedy DA, Stern SJ, Moretti M et al (2011) Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. Cancer Epidemiol 35:2–10

    Article  PubMed  CAS  Google Scholar 

  9. Zhang S, Hunter DJ, Hankinson SE et al (1999) A prospective study of folate intake and the risk of breast cancer. JAMA, J Am Med Assoc 281:1632–1637

    Article  CAS  Google Scholar 

  10. Baggott JE, Oster RA, Tamura T (2012) Meta-analysis of cancer risk in folic acid supplementation trials. Cancer Epidemiol 36:78–81

    Article  PubMed  CAS  Google Scholar 

  11. Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA, J Am Med Assoc 297:2351–2359

    Article  CAS  Google Scholar 

  12. Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161

    Article  PubMed  CAS  Google Scholar 

  13. Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377

    Article  PubMed  CAS  Google Scholar 

  14. Catalona WJ, Loeb S, Han M (2006) Viewpoint: expanding prostate cancer screening. Ann Intern Med 144:441–443

    Article  PubMed  Google Scholar 

  15. Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246

    Article  PubMed  CAS  Google Scholar 

  16. Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, J Am Med Assoc 279:1542–1547

    Article  CAS  Google Scholar 

  17. Gann PH, Ma J, Catalona WJ, Stampfer MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 167:2427–2434

    Article  PubMed  Google Scholar 

  18. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J (2009) Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 169:236–248

    Article  PubMed  Google Scholar 

  19. Chang SL, Harshman LC, Presti JC Jr (2010) Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 28:3951–3957

    Article  PubMed  Google Scholar 

  20. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100:1511–1518

    Article  PubMed  CAS  Google Scholar 

  21. Pelucchi C, Galeone C, Talamini R et al (2005) Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev 14:944–948

    Article  PubMed  CAS  Google Scholar 

  22. Tavani A, Malerba S, Pelucchi C et al (2012) Dietary folates and cancer risk in a network of case-control studies. Ann Oncol 23:2737–2742

    Article  PubMed  CAS  Google Scholar 

  23. Shannon J, Phoutrides E, Palma A et al (2009) Folate intake and prostate cancer risk: a case–control study. Nutr Cancer 61:617–628

    Article  PubMed  CAS  Google Scholar 

  24. Rossi E, Hung J, Beilby JP, Knuiman MW, Divitini ML, Bartholomew H (2006) Folate levels and cancer morbidity and mortality: prospective cohort study from Busselton, Western Australia. Ann Epidemiol 16:206–212

    Article  PubMed  Google Scholar 

  25. Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle EE (2006) Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 163:989–996

    Article  PubMed  Google Scholar 

  26. Johansson M, Appleby PN, Allen NE et al (2008) Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 17:279–285

    Article  PubMed  CAS  Google Scholar 

  27. Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW (2010) Serum levels of folate, lycopene, beta-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr 64:1235–1238

    Article  PubMed  CAS  Google Scholar 

  28. Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R et al (2003) Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 12:1271–1272

    PubMed  CAS  Google Scholar 

  29. Collin SM, Metcalfe C, Refsum H et al (2010) Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 19:1632–1642

    Article  PubMed  CAS  Google Scholar 

  30. Bassett JK, Severi G, Hodge AM et al (2012) Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes Control CCC 23:855–863

    Article  PubMed  Google Scholar 

  31. Verhage BA, Cremers P, Schouten LJ, Goldbohm RA, van den Brandt PA (2012) Dietary folate and folate vitamers and the risk of prostate cancer in The Netherlands Cohort Study. Cancer Causes Control CCC 23:2003–2011

    Article  PubMed  Google Scholar 

  32. Wien TN, Pike E, Wisloff T, Staff A, Smeland S, Klemp M (2012) Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open 2:e000653

    Article  PubMed  Google Scholar 

  33. Iyer R, Tomar SK (2009) Folate: a functional food constituent. J Food Sci 74:R114–R122

    Article  PubMed  CAS  Google Scholar 

  34. Piyathilake CJ, Robinson CB, Cornwell P (2007) A practical approach to red blood cell folate analysis. Anal Chem Insights 2:107–110

    PubMed  Google Scholar 

  35. Ulrich CM, Potter JD (2007) Folate and cancer–timing is everything. JAMA, J Am Med Assoc 297:2408–2409

    Article  CAS  Google Scholar 

  36. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ (2010) Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol 8:6

    Article  PubMed  Google Scholar 

  37. Shabbeer S, Williams SA, Simons BW, Herman JG, Carducci MA (2012) Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence. Cancer Prev Res (Phila) 5:229–239

    Article  CAS  Google Scholar 

  38. Petersen LF, Brockton NT, Bakkar A et al (2012) Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. BJU Int 109:788–795

    Article  PubMed  CAS  Google Scholar 

  39. Bistulfi G, Foster BA, Karasik E et al (2011) Dietary folate deficiency blocks prostate cancer progression in the TRAMP model. Cancer Prev Res (Phila) 4:1825–1834

    Article  CAS  Google Scholar 

  40. Tomaszewski JJ, Cummings JL, Parwani AV et al (2011) Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate 71:1287–1293

    PubMed  CAS  Google Scholar 

  41. Henderson RJ, Eastham JA, Culkin DJ et al (1997) Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 89:134–138

    Article  PubMed  CAS  Google Scholar 

  42. Ulrich CM (2008) Folate and cancer prevention–where to next? Counterpoint. Cancer Epidemiol Biomarkers Prev 17:2226–2230

    Article  PubMed  Google Scholar 

  43. Jackson MD, Tulloch-Reid MK, McFarlane-Anderson N et al (2012) Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr 8:199–207

    Article  PubMed  Google Scholar 

  44. Bostwick DG, Burke HB, Djakiew D et al (2004) Human prostate cancer risk factors. Cancer 101:2371–2490

    Article  PubMed  CAS  Google Scholar 

  45. Rota M, Scotti L, Turati F et al (2012) Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev 21:350–359

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Yueh-Ying Han

  2. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, A526 Crabtree Hall, Pittsburgh, PA, 15261, USA

    Ji Young Song & Evelyn O. Talbott

Authors
  1. Yueh-Ying Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ji Young Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evelyn O. Talbott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yueh-Ying Han.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 23 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, YY., Song, J.Y. & Talbott, E.O. Serum folate and prostate-specific antigen in the United States. Cancer Causes Control 24, 1595–1604 (2013). https://doi.org/10.1007/s10552-013-0236-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-013-0236-7

Keywords

Search

Navigation